Effects of Butylphthalide combined with Alteplase intravenous thrombolysis in treatment of patients with acute cerebral infarction
Objective:To observe effects of Butylphthalide combined with Alteplase intravenous thrombolysis in treatment of patients with acute cerebral infarction.Methods:A prospective study was conducted on 82 patients with acute cerebral infarction admitted to the hospital from January 2022 to January 2023.According to the random number table method,they were divided into observation group and control group,41 cases in each group.The control group was treated with intravenous thrombolysis with Alteplase,while the observation group was treated with oral Butylphthalide soft capsules on the basis of that of the control group.The National Institutes of Health stroke scale(NIHSS)score,the Barthel index(BI)score were compared between the two groups.Results:After the treatment,the NIHSS score and PRI and MPAR in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the BI scores in the two groups were higher than those before the treatment,and the those in observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).During the treatment,there were no obvious adverse reactions in the two groups.Conclusions:Butylphthalide combined with Alteplase intravenous thrombolysis in the treatment of acute cerebral infarction can improve the BI scores,and reduce the levels of platelet indexes and the NIHSS scores.Moreover,it is superior to single Alteplase intravenous thrombolysis treatment.
万方数据
维普
